Episode Details

Federal regulators have approved Eli Lillys new weight-loss pill, orforglipron, branded as Foundayo. Its the second daily oral option for obesity, similar to injectable GLP-one drugs, and will start shipping Monday. Prices range from $25 to $349 per month, depending on dose. Foundayo has shown promising results in clinical trials, with users losing weight, lowering blood pressure, and improving cholesterol. However, side effects were common, causing 5-10% of users to drop out. The FDA fast-tracked its approval, and its part of a push to make GLP-one drugs more accessible.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/40b6aae746c599c7